- Summit features specialized workshops and certification tracks alongside international faculty at the JW Marriott Cancún Resort & Spa
- Event is expected to draw more than 500 physicians, researchers, and regenerative medicine leaders to ISSCA’s flagship Cancún venue
- Global Summit contributes to ISSCA’s international education ecosystem and Global Stem Cells Group’s worldwide presence
FOR IMMEDIATE RELEASE
MIAMI, FL — The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced its 2026 Global Summit — ISSCA 125 — taking place September 25–27 at the JW Marriott Cancún Resort & Spa.
The Summit is expected to draw more than 500 physicians and professionals, with hundreds already registered, across specialized workshops and certification tracks including the organization’s flagship and peptide-medicine certifications, alongside international faculty, published authors, researchers, and physicians and leaders across regenerative medicine, longevity, and biotechnology.
ISSCA, founded in 2009, has trained more than 12,000 physicians across more than 45 countries to date. The Global Summit is positioned as a flagship contribution to ISSCA’s international education ecosystem and Global Stem Cells Group’s broader global footprint.
“Cancún has become something of a home base for ISSCA’s most ambitious programming,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “The Global Summit is where physicians from the widest range of countries come together in one place, and that’s exactly the kind of international network effect we’re trying to build.”
About Regenerative Medical Technology Group, Inc.
Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.
About ISSCA
The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), was founded in 2009 and has trained more than 12,000 physicians across more than 45 countries in regenerative medicine, longevity medicine, and related disciplines through certifications, fellowships, conferences, and online education.
